Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, January 13, 2021
OXGENE™ has announced the introduction of its self-labelling integral membrane (SLIM™) protein discovery system.
read more
Thursday, September 19, 2019
Caribou has granted Oxford Nanopore a worldwide, non-exclusive license under foundational CRISPR-Cas9 intellectual property controlled by Caribou for nanopore sequencing.
read more
Wednesday, August 08, 2018
Oxford Genetics has secured a contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community.
read more
Oxford Genetics announced a £7.5 million investment into its operations in the US and the UK by Mercia Technologies PLC, an existing investor, and Invesco Perpetual.
read more
Tuesday, December 20, 2016
Oxford Genetics Ltd, a biotech company that which specializes in DNA design, protein and viral expression systems, and cell line engineering, has secured a £1.61 million grant from Innovate UK. The funding will support a new research project ...
read more
Wednesday, September 13, 2017
Oxford Genetics has opened its first U.S. office located at the NGIN workplace near Kendall Square in the Cambridge district of Boston.
read more
Wednesday, October 26, 2016
Oxford Genetics Ltd, a biotech company which specializes in DNA design, protein expression optimization and cell line development technologies and services, has moved its operations to new state-of-the-art laboratories at The Oxford Science Park.
read more
Thursday, January 21, 2021
Oxford BioTherapeutics has selected a second bispecific program that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology candidate.
read more
Oxford Biomedica announced the UK MHRA has issued a Certificate of GMP compliance for the fourth GMP manufacturing suite within the Group’s new Oxbox manufacturing facility.
read more
Oxford Biomedica plc announced that it has completed the acquisition of ABL Europe SAS from Institut Mérieux SA.
read more
Mitsubishi Tanabe Pharma America announced Oxford BioDynamics has joined the REFINE-ALS study, which was designed to identify and measure specific biomarkers in people with ALS.
read more
Oxeltis and Molecular Forecaster Inc. (MFI), a computational chemistry company, announced a strategic partnership, leveraging the strengths of both organizations to offer the seamless integration of in silico design with high-quality chemical ...
read more
Tuesday, October 07, 2025
OXB, a cell and gene therapy CDMO, has signed and closed an asset purchase transaction to acquire a custom-built, state-of-the-art cell and gene therapy viral vector manufacturing facility in North Carolina from RTP Operating, LLC, a subsidiary of ...
read more
OWP Pharmaceuticals has chosen EVERSANA to provide commercialization support for the U.S. launch of SUBVENITE® (lamotrigine) oral suspension, a recently FDA-approved treatment for epilepsy and bipolar disorders.
read more
Indian pharmacovigilance consulting and drug safety services company Oviya MedSafe Pvt Ltd has
signed an agreement with British software development company Assured Information Systems Ltd to
combine the former's drug safety services with the ...
read more